[go: up one dir, main page]

ECSP10010051A - Derivados de bencimidazol e indol sustituidos por oxadiazol y oxazol como inhibidores de dgat1 - Google Patents

Derivados de bencimidazol e indol sustituidos por oxadiazol y oxazol como inhibidores de dgat1

Info

Publication number
ECSP10010051A
ECSP10010051A EC2010010051A ECSP10010051A ECSP10010051A EC SP10010051 A ECSP10010051 A EC SP10010051A EC 2010010051 A EC2010010051 A EC 2010010051A EC SP10010051 A ECSP10010051 A EC SP10010051A EC SP10010051 A ECSP10010051 A EC SP10010051A
Authority
EC
Ecuador
Prior art keywords
bencimidazol
oxazol
oxadiazol
dgat1 inhibitors
indol derivatives
Prior art date
Application number
EC2010010051A
Other languages
English (en)
Inventor
Gary Mark Coppola
Young-Shin Kwak
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010051A publication Critical patent/ECSP10010051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención proporciona derivados de bencimidazol e indol sustituidos por oxadiazolilo que son útiles para el tratamiento de las condiciones o los trastornos asociados con la actividad de DGAT1 en animales, en particular en seres humanos.
EC2010010051A 2007-09-28 2010-03-26 Derivados de bencimidazol e indol sustituidos por oxadiazol y oxazol como inhibidores de dgat1 ECSP10010051A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97606407P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
ECSP10010051A true ECSP10010051A (es) 2010-04-30

Family

ID=39971086

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010051A ECSP10010051A (es) 2007-09-28 2010-03-26 Derivados de bencimidazol e indol sustituidos por oxadiazol y oxazol como inhibidores de dgat1

Country Status (27)

Country Link
US (2) US7879850B2 (es)
EP (1) EP2205595B1 (es)
JP (1) JP5675359B2 (es)
KR (1) KR101616133B1 (es)
CN (1) CN101932576B (es)
AR (1) AR066169A1 (es)
AU (1) AU2008303541B2 (es)
BR (1) BRPI0817272A2 (es)
CA (1) CA2701053C (es)
CL (1) CL2008002871A1 (es)
CO (1) CO6251263A2 (es)
CR (1) CR11261A (es)
CU (1) CU20100049A7 (es)
EA (1) EA019347B1 (es)
EC (1) ECSP10010051A (es)
ES (1) ES2525703T3 (es)
IL (1) IL203797A (es)
MA (1) MA31707B1 (es)
MX (1) MX2010003264A (es)
MY (1) MY151551A (es)
NZ (1) NZ583285A (es)
PE (1) PE20090774A1 (es)
TN (1) TN2010000096A1 (es)
TW (1) TWI429642B (es)
UA (1) UA99305C2 (es)
WO (1) WO2009040410A1 (es)
ZA (1) ZA201000829B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
KR20090012349A (ko) 2006-05-30 2009-02-03 아스트라제네카 아베 아세틸 조효소 ａ 디아실글리세롤 아실트랜스퍼라제의 억제제로서의 치환된 5-페닐아미노-1,3,4-옥사디아졸-2-일카르보닐아미노-4-페녹시-시클로헥산 카르복실산
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
JP2012520886A (ja) * 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
NZ601526A (en) 2009-12-31 2014-07-25 Piramal Entpr Ltd Inhibitors of diacylglycerol acyl transferase
AU2011235301B2 (en) * 2010-03-30 2013-07-18 Novartis Ag Uses of DGAT1 inhibitors
WO2012044567A2 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
WO2012064569A1 (en) * 2010-11-08 2012-05-18 Merck Sharp & Dohme Corp. Imidazole derivatives
SG10201605304VA (en) 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
WO2013074387A1 (en) * 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Imidazole derivatives
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
JP6099753B2 (ja) 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
WO2014081996A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
BR112015011982A8 (pt) * 2012-11-23 2019-10-08 Glaxosmithkline Llc compostos inibidores de diacilglicerol aciltransferase, composição farmacêutica compreendendo estes e usos destes
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CN103087045B (zh) * 2013-01-11 2015-08-12 上海交通大学 一种苯并咪唑类杂环化合物、药物组合物及其用途
CN104610152A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类环丙基酰肼类gpr119激动剂、制备方法及其用途
CN104672144A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和硝基苯类gpr119激动剂、制备方法及其用途
KR102747096B1 (ko) 2018-03-16 2024-12-26 앤지 파마수티컬스 잉크. 심한 변비를 치료하기 위한 조성물 및 방법
JP2022507958A (ja) 2018-11-27 2022-01-18 ノバルティス アーゲー 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
JP7657151B2 (ja) * 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
CN117466863A (zh) * 2022-07-20 2024-01-30 盛睿泽华医药科技（苏州）有限公司 含芳香族取代基的苯并咪唑化合物及其制备方法和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024334A1 (en) 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
HUP0401748A3 (en) 2001-08-13 2011-03-28 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them
US20090286791A1 (en) 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
CA2509042A1 (en) * 2002-12-11 2004-06-24 Eli Lilly And Company Novel mch receptor antagonists
EP1590336B1 (en) 2003-01-27 2010-12-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
JP3878625B2 (ja) * 2003-06-20 2007-02-07 松下電器産業株式会社 振幅調整回路、モータ駆動制御装置、振幅調整方法、及びモータ駆動制御方法
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1653969A4 (en) * 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
US7700772B2 (en) 2004-02-12 2010-04-20 Merck Sharp & Dohme Corp. Amino heterocyclic modulators of chemokine receptor activity
WO2005108370A1 (ja) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
CA2572874A1 (en) 2004-07-02 2006-01-12 Sankyo Company Limited Urea derivative
US7759376B2 (en) 2004-10-15 2010-07-20 Bayer Healthcare Llc Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
CN101052618A (zh) 2004-10-29 2007-10-10 默克公司 用作治疗阿尔茨海默氏病的β－分泌酶抑制剂的2－氨基吡啶化合物
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
WO2006082952A1 (ja) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited アミド化合物
JP2008536947A (ja) 2005-04-19 2008-09-11 バイエル・フアーマシユーチカルズ・コーポレーシヨン アリールアルキル酸誘導体およびそれらの使用
AU2006245812B2 (en) 2005-05-10 2010-12-02 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US20090215779A1 (en) 2005-06-11 2009-08-27 Roger John Butlin Oxadiazole derivatives as dgat inhibitors
WO2007016538A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
EP1915341A2 (en) 2005-08-15 2008-04-30 Irm, Llc Compounds and compositions as tpo mimetics
EP2298770A1 (en) 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
EP1963313B1 (en) 2005-11-28 2012-11-14 Madrigal Pharmaceuticals, Inc. Inhibitors of diacylglycerol acyltransferase (dgat)
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
WO2007137107A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US20080015227A1 (en) 2006-05-19 2008-01-17 Kym Philip R Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
KR20090012349A (ko) 2006-05-30 2009-02-03 아스트라제네카 아베 아세틸 조효소 ａ 디아실글리세롤 아실트랜스퍼라제의 억제제로서의 치환된 5-페닐아미노-1,3,4-옥사디아졸-2-일카르보닐아미노-4-페녹시-시클로헥산 카르복실산
AU2007266890B2 (en) 2006-05-30 2011-02-17 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors
CN101460469A (zh) 2006-06-06 2009-06-17 阿斯利康(瑞典)有限公司 化合物
DE602007012875D1 (de) 2006-06-08 2011-04-14 Astrazeneca Ab Benzimidazole und ihre verwendung zur behandlung von diabetes
GB0611507D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
US20120065196A1 (en) 2006-07-21 2012-03-15 Shuji Kitamura Amide compounds
CA2669884A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
CN101636155A (zh) 2006-11-29 2010-01-27 艾博特公司 二酰甘油o-酰基转移酶1型酶的抑制剂
US20100093733A1 (en) 2007-02-15 2010-04-15 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en) 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
JP2010526781A (ja) 2007-04-30 2010-08-05 アボット・ラボラトリーズ ジアシルグリセロールｏ−アシル転移酵素１型酵素の阻害剤
CA2685524A1 (en) 2007-04-30 2008-11-06 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
AU2008253118B2 (en) 2007-05-22 2013-11-21 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8115011B2 (en) * 2007-05-22 2012-02-14 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8153644B2 (en) * 2007-05-22 2012-04-10 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8058299B2 (en) * 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
WO2008148851A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
WO2008148840A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
PA8783601A1 (es) 2007-06-08 2009-01-23 Janssen Pharmaceutica Nv Derivados de piperidina/piperazina
WO2009011285A1 (ja) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
MX2010001848A (es) 2007-08-17 2010-03-10 Astrazeneca Ab Derivados de oxadiazol como inhibidores de diacilglicerolaciltrans ferasa (dgat).
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009071483A1 (en) 2007-12-07 2009-06-11 Via Pharmaceuticals, Inc. 1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors
CA2707660A1 (en) 2007-12-20 2009-07-02 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
CN101981012A (zh) 2008-03-26 2011-02-23 第一三共株式会社 新的四氢异喹啉衍生物
PE20140572A1 (es) 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
MX2011000628A (es) * 2008-07-15 2011-02-25 Novartis Ag Derivados de heteroarilo como inhibidores de dgat1.

Also Published As

Publication number Publication date
EP2205595B1 (en) 2014-09-10
KR101616133B1 (ko) 2016-04-27
AU2008303541B2 (en) 2012-06-07
EA201000428A1 (ru) 2010-10-29
CA2701053A1 (en) 2009-04-02
IL203797A (en) 2014-01-30
MX2010003264A (es) 2010-04-01
CR11261A (es) 2010-04-26
CU23901B1 (es) 2013-06-28
KR20100071048A (ko) 2010-06-28
CN101932576A (zh) 2010-12-29
CU20100049A7 (es) 2011-09-21
AR066169A1 (es) 2009-07-29
MY151551A (en) 2014-06-13
AU2008303541A1 (en) 2009-04-02
US7879850B2 (en) 2011-02-01
TW200914449A (en) 2009-04-01
US20090186891A1 (en) 2009-07-23
TWI429642B (zh) 2014-03-11
UA99305C2 (ru) 2012-08-10
CA2701053C (en) 2016-08-23
ES2525703T3 (es) 2014-12-29
NZ583285A (en) 2012-05-25
TN2010000096A1 (en) 2011-09-26
EP2205595A1 (en) 2010-07-14
BRPI0817272A2 (pt) 2015-06-16
CL2008002871A1 (es) 2009-05-15
ZA201000829B (en) 2010-12-29
CO6251263A2 (es) 2011-02-21
MA31707B1 (fr) 2010-09-01
PE20090774A1 (es) 2009-07-17
US20110077277A1 (en) 2011-03-31
CN101932576B (zh) 2014-09-10
EA019347B1 (ru) 2014-03-31
JP5675359B2 (ja) 2015-02-25
WO2009040410A1 (en) 2009-04-02
JP2011501735A (ja) 2011-01-13
US8217065B2 (en) 2012-07-10

Similar Documents

Publication Publication Date Title
ECSP10010051A (es) Derivados de bencimidazol e indol sustituidos por oxadiazol y oxazol como inhibidores de dgat1
ECSP088782A (es) Compuestos nuevos
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
UY37487A (es) Amidas heterocíclicas como inhibidores de quinasa
CR11871A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3- dioxigenasa
ECSP14020545A (es) Compuestos de indol e indazol que activan la ampk
CO6660445A2 (es) Compuestos heterocíclicos agonistas del receptor ip
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
UY30640A1 (es) Compuestos
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
MX2010005047A (es) Inhibidores de aldh-2 en el tratamiento de enfermedades psiquiatricas.
UY30706A1 (es) Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
CL2015003037A1 (es) Derivados de triazina
CR20150148A (es) Azaindolinas
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
UY31700A (es) Tiazolil-dihidro-indazoles
UY31423A1 (es) Compuestos de indolina
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de
UY31648A1 (es) El uso de derivados del lúpulo para controlar parásitos en animales